TITLE

Depakote ER goes generic

PUB. DATE
April 2009
SOURCE
Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the marketing approval attained by Wockhardt USA and Mylan Pharmaceuticals Inc. for Depakote ER. It mentions that the two pharmaceutical companies will have their 180 days in marketing the newly FDA-approved medication. Moreover, this drug is intended to cure and alleviate several types of seizure.
ACCESSION #
37246726

 

Related Articles

  • Bertek: Apokyn to make small moves in market.  // PharmaWatch: CNS;June 2004, Vol. 3 Issue 6, p4 

    Reports on the approval of the U.S. Food and Drug Administration to Apokyn as the first Parkinson's disease immobility treatment. Role of Bertek Pharmaceuticals Inc. in the marketing of Apokyn; Definition of Parkinson's disease; Benefits of the drug marketing for Bertek.

  • Mylan Is First to Market With a Version of Actos.  // Chain Drug Review;9/24/2012, Vol. 34 Issue 16, p111 

    The article reports that Mylan Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has awarded it 180 days of generic marketing exclusively on both the pioglitazone hydrochloride and metformin hydrochloride tablets.

  • Mylan wins FDA approval for additional strengths of antipsychotic drug.  // PharmaWatch: CNS;Sep2009, Vol. 8 Issue 9, p20 

    The article reports that U.S. Food and Drug Administration (FDA) approved the abbreviated new drug application (ANDA) for haloperidol tablets of the Mylan Pharmaceuticals Inc. It mentions that the approval of the haloperidol tablets adds strength to the Mylan's marketed haloperidol in various...

  • Mylan wins FDA approval for generic depression drug.  // PharmaWatch: CNS;May2010, Vol. 9 Issue 5, p9 

    The article reports on the approval of Food & Drug Administration (FDA) to the abbreviated new drug application (ANDA) of Mylan Pharmaceuticals Inc. for its bupropion hydrochloride extended-release tablets.

  • Mylan receives FDA approval for generic version of Effexor XR capsules.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p24 

    The article reports on the final approval issued by the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of Venlafaxine Hydrochloride extended-release capsules from Mylan Pharmaceuticals Inc.

  • Mylan launches generic version of schizophrenia drug.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p26 

    The article offers updates on the developments of fully integrated pharmaceutical company Mylan Pharmaceuticals Inc., one on the launch of schizophrenic drug risperidone and the 169 pending approval of its abbreviated new drug applications (ANDAs) by the U.S. Food and Drug Administration (FDA).

  • FDA Clears New Products for Market.  // Chain Drug Review;1/21/2013, Vol. 35 Issue 2, p38 

    The article informs that the U.S. Food and Drug Administration has approved Mylan Pharmaceuticals Inc.'s orally disintegrating tablets containing rizatriptan benzoate.

  • MYLAN RECEIVES FINAL FDA APPROVALS FOR GENERIC VERSIONS OF LAMICTAL TABLETS AND LAMICTAL CD.  // Psychiatry (1550-5952);Feb2009, Vol. 6 Issue 2, p14 

    The article reports that two subsidiaries of Mylan Inc. have received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for lamotrigine tablets. The ANDAs were approved for the 25mg-200mg strengths of the generic version of...

  • Injectable anticonvulsant.  // Geriatrics;Nov96, Vol. 51 Issue 11, p20 

    Reports on the US Food and Drug Administration's (FDA) approval of Fostphenytoin sodium injection for use as anticonvulsant drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics